The Business Research Company’s report on the Juvenile Macular Degeneration Treatment Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
How are market drivers shaping the future growth trajectory of the juvenile macular degeneration treatment industry?
The increasing prevalence of retinal disorders is expected to propel the growth of the juvenile macular degeneration treatment market going forward. Retinal disorders refer to a group of conditions that affect the retina, the light-sensitive layer at the back of the eye, leading to vision impairment or loss. Retinal disorders are increasing due to the rising prevalence of diabetes, leading to conditions such as diabetic retinopathy that damage the retina over time. Juvenile macular degeneration treatments enhance retinal disorder management by preserving vision through early intervention, making them crucial for young patients. For instance, in November 2024, according to the report published by Retina Australia, an Australia-based non-profit organization, in Australia, approximately 19,000 individuals, or about 1 in 1,380 people, are estimated to be living with an inherited retinal disease (IRD). Furthermore, according to the National Eye Institute, a US-based institute of health, the number of Americans with advanced age-related macular degeneration (AMD) is expected to increase from the current 2.1 million to 3.7 million by 2030. Therefore, the increasing prevalence of retinal disorders is driving the growth of the juvenile macular degeneration treatment market.
Access Your Free Sample of the Global Juvenile Macular Degeneration Treatment Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=23433&type=smp
What is the estimated market size of the juvenile macular degeneration treatment sector by 2029, based on current forecasts?
The juvenile macular degeneration treatment market size has grown strongly in recent years. It will grow from $1.28 billion in 2024 to $1.39 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to increasing prevalence of genetic eye disorders, increasing investment in ophthalmic research, increasing focus on pediatric eye care, rising prevalence of vision impairment among children, and growing integration of artificial intelligence in eye care diagnostics.
The juvenile macular degeneration treatment market size is expected to see strong growth in the next few years. It will grow to $1.88 billion in 2029 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to a rise in the geriatric population, a rise in ophthalmic biotechnology startups, an increasing focus on targeted drug delivery systems, an increasing number of clinical trials, and increasing investment in gene therapy. Major trends in the forecast period include advancements in genetic testing, the development of gene therapies, stem cell research, regulatory support for innovative therapies, and personalized medicine approaches.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=23433&type=smp
Who are the top players in the juvenile macular degeneration treatment market?
Major companies operating in the juvenile macular degeneration treatment market are F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, AbbVie Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., Santen Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Samsung Bioepis Co. Ltd., Spark Therapeutics Inc., Polpharma Biologics S.A., OrCam Technologies Ltd., Alkeus Pharmaceuticals Inc., Bioeq AG, NuEyes Technologies Inc., Coherus BioSciences Inc., eSight Eyewear Inc., MeiraGTx Holdings plc, Kubota Pharmaceutical Holdings Co. Ltd.
What trends will propel the growth and evolution of the juvenile macular degeneration treatment market?
Major companies operating in the juvenile macular degeneration treatment market are focusing on developing innovative solutions, such as dual adeno-associated viral (AAV) vectors, to enhance gene therapy delivery and improve treatment efficacy for patients with juvenile macular degeneration. A dual adeno-associated viral (AAV) vector is a gene therapy approach that uses two AAV vectors to deliver large therapeutic genes that exceed the packaging capacity of a single AAV. For instance, in March 2025, SpliceBio, a Spain-based biotechnology company, announced the first patient dosing in its Phase 1/2 ASTRA study for SB-007, a dual AAV vector gene therapy designed to restore full-length ABCA4 protein expression. The therapy aims to provide a potential treatment for juvenile macular degeneration (stargardt disease), an inherited retinal disorder with no approved treatments, by addressing all patients regardless of their mutations. This milestone marks a significant step toward developing effective gene therapies for rare retinal diseases.
Which geography holds the highest juvenile macular degeneration treatment market share?
North America was the largest region in the juvenile macular degeneration treatment market in 2024. The regions covered in the juvenile macular degeneration treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
How do different segments contribute to the overall expansion of the juvenile macular degeneration treatment market?
The juvenile macular degeneration treatment market covered in this report is segmented –
1) By Type: Wet Age-Related Macular Degeneration, Dry Age-Related Macular Degeneration
2) By Treatment: Devices, Drugs, Surgery
3) By Application: Vision Preservation, Disease Management, Symptom Relief, Preventive Care, Clinical Trials
4) By Sales Channel: Hospitals, Ambulatory Surgical Centres, Other Sales Channel
Subsegments:
1) By Wet Age-Related Macular Degeneration: Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapy, Photodynamic Therapy (PDT), Laser Therapy
2) By Dry Age-Related Macular Degeneration: Nutritional Supplements, Gene Therapy, Stem Cell Therapy
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23433
What defines the structure and scope of the juvenile macular degeneration treatment market?
Juvenile macular degeneration (stargardt disease) treatment refers to a range of strategies aimed at managing vision loss and improving quality of life for individuals affected by this genetic eye disorder. It is caused by genetic mutations that damage the macula, the central part of the retina, leading to gradual vision loss and difficulty with tasks like reading and recognizing faces.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
